|
Endometrial Carcinoma
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
|
Endometrial Carcinoma
|
0.700 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Endometrial Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The discovery of activating FGFR2 mutations in endometrial carcinoma raises the possibility of employing anti-FGFR molecularly targeted therapies in patients with advanced or recurrent endometrial carcinoma.
|
17525745 |
2007 |
|
Endometrial Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Here, we show that shRNA knockdown of FGFR2 or treatment with a pan-FGFR inhibitor, PD173074, resulted in cell cycle arrest and induction of cell death in endometrial cancer cells with activating mutations in FGFR2.
|
18757403 |
2008 |
|
Endometrial Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We also observed a nonsignificant inverse association with rs889312 (MAP3K1) variant carriers [OR = 0.85 (95% CI: 0.68-1.05)] and rs1219648 (FGFR2) variant carriers [OR= 0.86 (95% CI: 0.69-1.06) and endometrial cancer risk.
|
18785201 |
2008 |
|
Endometrial Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Taken into account with our recent discovery of activating FGFR2 mutations in endometrial cancer, we suggest that FGFR2 may join the list of genes that play context-dependent opposing roles in cancer.
|
19147536 |
2009 |
|
Endometrial Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In vitro studies have shown that endometrial cancer cell lines with activating FGFR2 mutations are selectively sensitive to a pan-FGFR inhibitor, PD173074.
|
19243295 |
2009 |
|
Endometrial Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Mutational activation of one member of this receptor family, FGFR2, is a frequent event in endometrioid endometrial cancer.
|
20106510 |
2010 |
|
Endometrial Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Three of 43 (7%) endometrial carcinomas harbored FGFR2 exon 7 mutations.
|
21285871 |
2011 |
|
Endometrial Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Cytoplasmic expression of FGFR2 was higher in endometrial carcinoma when compared with the atrophic endometrium from the same patients (P=0.0283), but was lower in comparison with normal endometrium from women in the menstrual cycle.
|
21725289 |
2011 |
|
Endometrial Carcinoma
|
0.700 |
Biomarker
|
disease |
CTD_human |
Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase.
|
21936542 |
2011 |
|
Endometrial Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Mutations in multiple oncogenes including KRAS, CTNNB1, PIK3CA and FGFR2 have been identified in endometrial cancer.
|
22383975 |
2012 |
|
Endometrial Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Together these data suggest a potential therapeutic benefit to combining an FGFR inhibitor with standard chemotherapeutic agents in endometrial cancer therapy particularly in patients with FGFR2 mutation positive tumors.
|
23060048 |
2012 |
|
Endometrial Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In vivo, dovitinib and NVP-BGJ398 significantly inhibited the growth of FGFR2-mutated endometrial cancer xenograft models.
|
23443805 |
2013 |
|
Endometrial Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to examine the therapeutic potential of a rational drug combination based on the simultaneous targeting of mutant-FGFR2 and mTOR-driven signaling pathways in endometrial cancer cells.
|
23468082 |
2013 |
|
Endometrial Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Finally, the identification of 3 likely activating mutations in the tyrosine kinase receptor FGFR2, analogous to those reported in ovarian and endometrial carcinoma, point to potential therapeutic avenues for a subset of cases.
|
23778141 |
2013 |
|
Endometrial Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
EC cell lines expressing wild-type FGFR2 were relatively resistant to all inhibitors, whereas EC cell lines expressing mutated FGFR2 showed differential sensitivity.
|
23908597 |
2013 |
|
Endometrial Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
These findings suggest that combinatory therapies using dovitinib plus ICI182.780 treatment can be truly effective in patients with endometrial carcinomas carrying FGFR2 mutations.
|
24448819 |
2014 |
|
Endometrial Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
DNAs were extracted from 72 cases of fresh-frozen endometrial cancer tissues for FGFR2 mutational analysis by HRM analysis.
|
25517871 |
2015 |
|
Endometrial Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Of 248 patients with FGFR2 prescreening results, 27 (11%) had FGFR2(mut) endometrial cancer.
|
25981814 |
2015 |
|
Endometrial Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
However, AZD4547 has not been examined yet against FGFR2 mutant-driven endometrial cancers.
|
26294741 |
2015 |
|
Endometrial Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
AP24534 caused substantial reductions in ERK phosphorylation, PLCγ signaling and STAT5 signal transduction on ECs bearing FGFR2 activating mutations.
|
26574622 |
2016 |
|
Endometrial Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Combination of FGFR and AKT inhibition in an FGFR2-mutated endometrial cancer xenograft model enhanced modulation of transcript biomarkers from the PI3K/AKT pathway and tumor growth inhibition.
|
27550940 |
2016 |
|
Endometrial Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Using Cox regression analysis adjusting for known prognostic factors, patients with FGFR2 mutation had significantly (p<0.025) shorter progression-free survival (PFS; HR 1.903; 95% CI 1.177-3.076) and endometrial cancer specific survival (ECS; HR 2.013; 95% CI 1.096-3.696).
|
28314589 |
2017 |
|
Endometrial Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We tested the cytotoxicity of AL3818 on a panel of 7 human endometrial cancer cell lines expressing either wild-type or mutant FGFR2 and also assessed the in vivo antitumor efficacy in a murine, orthotopic AN3CA endometrial cancer model.
|
28953502 |
2018 |